Go to Page # Page of 20
loading

Novel Checkpoints in Immuno-Oncology

 Markus Metzger PhD
  19th-Mar-2018
Description: This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.
Views: 1375
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Innate Pharma
 ‐ More of their Presentations
Contents:
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY

KIR
NKG2A

NKp46

C5aR

HALF-YEAR RESULTS
Tumor
antigen

KIR3DL2

CD39
MICA/B

CD73

SEPTEMBER 18, 2017

FORWARD LOOKING STATEMENT
This document has been prepared by Innate Pharma S.A. (the
“Company”) solely for the purposes of a presentation to
investors concerning the Company. This document is not to be
reproduced by any person, nor to be distri ... See more

Recent Presentations

...
01 October, 2019
...
30 September, 2019
OHWRC
28 September, 2019